Laura Soucek, CEO of Peptomyc, one of the most Innovative Life Sciences Start-up of BioFIT 2018, reveals information on Peptomyc and explains why they attend BioFIT, and in particular why they applied to the Start-up Slams.

What is Peptomyc?

Peptomyc is developing new peptide therapies for the treatment of cancer patients. Our peptides are able to attack Myc, a protein required by cancer cells – but not normal cells -, to divide, thrive and survive treatments. That means that, attacking Myc, we can selectively kill cancer cells without damaging normal tissues.

Why your therapy is innovative?

Our therapy is innovative because 1. nobody has managed to efficiently attack Myc before; 2. because it  is effective against cancer but gentle on other tissues, sparing the patient from toxic side effects; and 3. last but not least, because it is potentially applicable to all types of cancer. It is the opposite of personalized medicine: it is universal medicine.

Laura Soucek, CEO of Peptomyc and Marie-Eve Beaulieu, CSO

Why did you apply to the Start-up Slams?

Because it seemed like a great opportunity to gain exposure in one of the biggest events in Europe for early start-ups and investors. It is also a way to take advantage of speed mentoring from the expert juries and a nice platform to establish useful networks.

Why did you attend BioFIT?

We are now in pre-clinical regulatory studies and, if everything goes well, we should be able to start clinical trials at the beginning of 2020. That requires a next round of investment by the end of 2019. At BioFIT we looked for the chance to meet with smart investors that could be interested in our project.

What do you retain from these two days?

It is a very nice specialized conference, which favors informal and formal contacts between start-ups, VCs and CROs. It is less intimidating and more friendly than other international events, especially for early stage biotech companies.

What will you say to someone which aims at appling to the Start-up Slams in 2019?

Go for it! It is a very productive experience and a chance to learn from peers and from expert jury members.

Caroline-Barelle

Caroline Barelle, CEO of Elasmogen, explains why they attend BioFIT, and in particular why they applied to the Start-up Slams.

Can you describe your innovation in few words?

Next generation therapeutic biologics . These are essentially naturally occurring small antibody-like molecules that form part of the adaptive immune system of sharks. We call these soloMERs.

How is your technology innovative?

Given the small size (better tissue penetration), stability (novel routes of administration), novel structure (binds cryptic or hidden epitopes on the target) and simple structure, the team saw the opportunity to develop these into a new class of therapeutic drugs. We have succeeded in re-formatting these to bind more than one disease target and in isolating soloMERs that bind unique parts of the target disease molecule of all which results in increased potency.

Why did you apply to the Start-up Slams?

The opportunity to headline our company at such a prestigious conference provides the benefit of presenting in front of a great mixed audience of investors, pharma, biotech and academics.

Why did you attend BioFIT?

The quality of participants from all corners of the life science sector

What do you retain from these two days?

 I thought it was a great conference. It was the right size to network and reach out and meet those I wanted to. There was the right balance of investors, pharma, biotech and academics there and I was able to benefit from the one-2-one partnering meetings as well as enjoy the panel debates and discussions.

What will you say to someone which aims at appling to the Start-up Slams in 2019?

Go for it! I remain amazed that we were winners given the quality of the other companies but regardless just participating gives you a platform in front of a great panel and a great audience.

 

More information on www.elasmogen.com

Save the date and the place
BioFIT | 8th edition
December 10th and 11th, 2019
Marseille, France

With a record-breaking edition, especially in terms of the number of participants (1,300+ from 35 countries), BioFIT confirms its status as the leading European partnering event for early-stage deals and investment rounds in the field of Life Sciences.

During BioFIT 2018, a unique partnership between three powerful ecosystems – the Sud Provence-Alpes-Côte d’Azur Region, the Grand Est Region and the Hauts-de-France Region – has been announced.

Thanks to a committed collaboration between the competitiveness clusters Eurobiomed, BioValley France and the Nutrition-Health-Longevity cluster, as well as Eurasanté and the local authorities of these three territories, BioFIT will now deploy its anchoring alternately between the cities of Marseille (2019), Strasbourg (2020) and Lille (2021).

Register now and save up to € 150 thanks to the “Super Early Bird” offer!

The two most innovative start-ups who have been awarded during BioFIT 2018 are:

Emaslogen

Elasmogen Ltd is discovering and developing soloMER™s for the treatment of auto-immune mediated, inflammatory diseases. Utilising its unique soloMER™ platform, Elasmogen exploits the power of biologics as drugs but in small, simple, and stable formats that are amenable to site-specific delivery.

www.elasmogen.com

Peptomyc

Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.

www.peptomyc.com

Banner BF Platform

The partnering platform to pre-organise one-to-one meetings with the BioFIT participants is open!

Don’t hesitate to go make the best use out of it to leverage your time on site:

Go fill in your profile with the maximum of keywords on the platform (and make sure to publish it in order to be visible to other participants) and start sending meeting requests.

This is the perfect opportunity to create collaborations!

 

Welcome Reception

Arriving in Lille on December 3rdDiscover the charm of the city of Lille during Christmas time

The Welcoming Party will take place in the Omnia bar (9, rue Esquermoise, Lille) on December 3rd from 6.30 pm. What’s planned? Drinks, tapas and a ferris wheel ride to admire Lille from above!
[/vc_column_text]

Registration for the Welcome Reception is free. Register now by completing the form below:

[/vc_column][/vc_row]

Many thanks to VIB for joining BioFIT 2018 as a Bronze Sponsor!

 VIB is a life sciences research institute, based in Flanders, Belgium. They perform basic research with a strong focus on translatin​g scientific results into pharmaceutical, agricultural and industrial applications.

Join key BioFIT 2018 sponsors such as Bayer, RocheMSDBoehringer Ingelheim, Pfizer and LFB, to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

 

They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.

For more information about the sponsorship opportunities, visit the dedicated site page.

The BioFIT Steering Committee is glad to announce the BioFIT 2018 preliminary conference programme:

PLENARY SESSION: Seed funds crossing borders: How far and how fast is the early-stage investment market in Biotech globalising?

Globalisation of seed investment can be seen as traditionally geographically anchored, now early-stage investors tend to invest in more diversified areas. Where does the money come from? How far is this evolution towards more global funds going? How fast is it going in the investment community? Will it make the investors more risk taking, will it change the risk landscape? Isn’t there today an ill-balance between the geographical origin of the investment capacities and the areas where projects needing equity investment are teeming?

TRACK 1: Best practices in academia-industry R&D collaborations

  • Artificial Intelligence to speed-up drug discovery: The revolutionary road to advance innovation.
  • A prospective overview of the forthcoming cross-sectorial collaborations and licensing deals between human and animal health
  • Beyond shared means, common strategies to collectively succeed
  • Patient organisations to join the pharma-biotech-academia trio: Is a fourth musketeer calling for a new way to manage alliances?

TRACK 2: Nurturing and licensing early-stage assets

  • What is the right balance between equity, royalties, collaborative research income for the academic institutions in the process of spinning out companies?
  • An overview of the recent joint initiatives to derisk academic-origin assets
  • Questioning TTOs financing models: Could their expected financial outcome bias the tech transfer process?
  • Under pressure: How does the urge to bring rare disease therapies create a new range of business models or collaborative models?

TRACK 3: Early-stage innovation: Identify the right funding sources

  • Are philanthropic and alternative sources of soft funding always a free lunch?
  • Shaping your start-up for an industrial exit or an IPO: Are there choices to be made at the very initial stage?
  • Are immunotherapies a new investment Eldorado?
  • Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?